Langerhans cell histiocytosis, unifocal bone

Unifocal bone Langerhans cell histiocytosis (LCH) is a solitary osteolytic lesion produced by clonal proliferation of CD1a-positive, CD207 (Langerin)-positive Langerhans-type dendritic cells admixed with eosinophils and other inflammatory cells.[1][2] It is the single-system, single-site end of the LCH spectrum and is the form historically termed eosinophilic granuloma.[3] Once debated as reactive versus neoplastic, LCH is now classified as an inflammatory myeloid neoplasm driven by activating MAPK-pathway mutations, most often BRAF V600E; in solitary low-risk disease these alterations are typically restricted to differentiated myeloid/dendritic precursors rather than self-renewing hematopoietic stem cells, which correlates with its indolent behavior.[2][3][4]

In the jaws the signature appearance is a sharply demarcated "punched-out" radiolucency that destroys alveolar bone from the mid-root level, producing the classic "floating teeth".[5][6][7] Behavior is usually benign and self-limiting, and management is correspondingly conservative—confirmatory biopsy with curettage, often with intralesional corticosteroid, and in many cases observation.[3][8] The principal caveats are confirming that disease is truly unifocal through staging and recognizing craniofacial sites that carry central nervous system (CNS) risk.[3][8]

Current classification places LCH in the "L group" of histiocytoses alongside Erdheim–Chester disease.[4] Disease is stratified by extent into single-system (unifocal or multifocal) and multisystem (with or without risk-organ involvement) categories; this article addresses single-system, single-site osseous disease.[2]

The historical eponymic triad—eosinophilic granuloma (localized bone), Hand–Schüller–Christian disease (multifocal), and Letterer–Siwe disease (disseminated)—was unified under "histiocytosis X" by Lichtenstein and later renamed Langerhans cell histiocytosis after Birbeck granules linked the lesional cell to the epidermal Langerhans cell. "Eosinophilic granuloma" remains a useful alias for solitary bone LCH but is best accompanied by the modern term, since the older labels predate current biologic understanding.[3][10]

LCH is predominantly a disorder of childhood, with an annual incidence of roughly 5–9 cases per million children younger than 15 years and about 1–2 per million adults, and a slight male predominance.[1][4] Single-system disease accounts for the majority of cases and carries an excellent prognosis.[2]

• Skeletal predominance: bone is the most frequently involved system, affected in roughly 60%–80% of patients; solitary lesions are typical of low-risk disease.[1][8][11]
• Jaw involvement: the jaws are involved in approximately 10%–20% of LCH cases, with a strong predilection for the mandible; isolated maxillary involvement is comparatively uncommon.[13]
• Intrajaw distribution: within the jaws, the posterior mandible—particularly the molar region and alveolar bone—is the most common site.[13][14]
• Age in the jaws: oral/jaw lesions are reported across ages but cluster in children and young adults; jaw series report a mean age near the mid-teens, while solitary jaw lesions can present in adults and may then be mistaken for odontogenic or inflammatory disease.[12][15]

Jaw LCH most often presents with localized pain and swelling, and the lesion may be the first or only manifestation of disease.[15][16] Because alveolar bone is preferentially destroyed, periodontal-type signs dominate when the alveolus is involved.

• Common findings: pain, facial or intraoral swelling, gingival inflammation or hyperplasia, bleeding, and loosening or displacement of teeth ("drifting" teeth).[10][13][16]
• Mucosal change: overlying erythema, ulceration, or a soft-tissue mass; exophytic gingival lesions may occur with or without underlying bone destruction.[13][16]
• Pediatric clues: premature eruption and precocious exfoliation of primary teeth.[11]
• Tempo: typically indolent, developing over weeks to months; some lesions regress spontaneously, while others enlarge and cause mechanical compromise.[11][17]

Red flags that argue against purely local disease and should prompt full staging include polyuria/polydipsia (arginine vasopressin deficiency from pituitary involvement), chronic otorrhea or aural mass, proptosis, skin rash, lymphadenopathy, hepatosplenomegaly, bone pain at other sites, and cytopenias.[1][8][18]

Location and distribution

Jaw LCH favors the posterior mandible, especially the molar region and ramus/body, with the maxilla involved less often.[12][13][14] Lesions are centered either within the medullary bone (intraosseous type) or within the alveolar process adjacent to tooth roots (alveolar type); the intraosseous pattern predominates in jaw series.[15] By definition the unifocal form is a solitary lesion, which must be confirmed against the multifocal, moth-eaten, multi-quadrant pattern of more extensive skeletal disease.[13]

Periphery and shape

The hallmark is a well-defined radiolucency with a "punched-out" margin that is characteristically noncorticated.[5][6] Borders are sharply demarcated in indolent lesions but may be ragged or ill-defined when the lesion is active or rapidly growing, contributing to overlap with infection and malignancy.[14][15] Lesions are usually round to ovoid; adjacent discrete lucencies may enlarge and coalesce into a larger irregular zone of destruction over time.[6]

Internal architecture

The lesion is predominantly radiolucent with loss of the normal trabecular pattern and no true internal matrix or mineralization.[6][14] It is most often unilocular, though a pseudomultilocular appearance can occur; expansile lesions may show thin residual bony septa.[13][15] Perilesional reactive sclerosis is sometimes present, particularly in more chronic lesions.[15][19]

Effects on teeth and the alveolar process

When the alveolus is involved, destruction characteristically begins at the mid-root level rather than at the crestal margin, distinguishing it from the crest-down bone loss of periodontitis.[6] Progressive periradicular bone loss leaves teeth apparently suspended within the radiolucency—the "floating teeth" (floating-tooth) sign.[5][7][14] Loss of lamina dura, displacement of teeth, and interference with eruption may be seen; frank root resorption is uncommon.[11][16] A periapical lucency around a vital tooth can closely imitate endodontic pathology.[12]

Cortical involvement, growth pattern, and extent

Cortical thinning, erosion, and perforation occur as the lesion enlarges, frequently accompanied by an adjacent soft-tissue mass.[14][19] A periosteal reaction—solid, lamellated, or occasionally sunburst-type—has been reported in mandibular lesions and adds to the differential overlap with osteomyelitis and sarcoma.[14][19] Inferior alveolar canal and cortical margins may be displaced or destroyed; destructive but non-sclerotic expansion is typical.[15]

Recognized variants and correlates

Two jaw patterns are described: intraosseous lesions centered in medullary bone and alveolar lesions centered on the periodontium.[15] In the calvaria and skull base, correlative features include beveled-edge lucencies, the "hole-within-a-hole" appearance from unequal destruction of the two tables, and a central button sequestrum—useful when disease extends beyond the tooth-bearing bone.[7][19]

Sectional and functional imaging is not required to characterize a solitary jaw lucency but materially affects confirmation that disease is unifocal and guides staging.

Cross-sectional characterization

Lesions are lytic and expansile with an associated soft-tissue component; features such as periosteal new bone, perilesional sclerosis, fluid-like attenuation/signal, and adjacent inflammatory change mean jaw LCH closely mimics osteomyelitis.[15] On MRI, lesions are low on T1, intermediate-to-high on T2, and enhance markedly; relatively high apparent diffusion coefficient values favor LCH over malignant tumors and help guide biopsy.[14][19]

Whole-body staging

Because a jaw lesion may herald multifocal or multisystem disease, staging is essential. LCH lesions are FDG-avid, and PET/CT-based staging improves lesion detection and risk assignment, though small lesions can be missed.[8][19][20] A skeletal survey and, when indicated, dedicated brain/pituitary MRI complete evaluation for additional sites and CNS-risk involvement.[8]

A solitary, sharply marginated mandibular radiolucency with alveolar destruction in a child or young adult should raise LCH, but its appearance is nonspecific and overlaps with inflammatory, odontogenic, and malignant processes; tissue diagnosis is required.[14][15] The highest-yield alternatives follow.

The most dangerous pitfall is misreading an apical LCH lucency around a vital tooth as endodontic or periodontal disease, leading to inappropriate root canal therapy or extraction while disease progresses and systemic involvement goes unstaged.[12] Any periapical or alveolar lucency that fails to behave as expected—vital teeth, no clear odontogenic source, or poor response to conventional therapy—warrants biopsy with full immunophenotyping and MAPK-pathway molecular testing.[8][25]

Diagnosis rests on identifying lesional Langerhans cells: large mononuclear histiocytes with abundant eosinophilic cytoplasm and characteristic grooved, folded, or reniform ("coffee-bean") nuclei with fine chromatin and inconspicuous nucleoli.[8][14] These cells lie in sheets within a polymorphous background rich in eosinophils, with admixed histiocytes (including multinucleated forms), lymphocytes, and neutrophils; the infiltrate is not usually plasma-cell rich.[8] Eosinophilic microabscesses and areas of necrosis may be present and partly explain the "eosinophilic granuloma" designation.[10][26]

Immunophenotype and ultrastructure

Lesional cells are positive for CD1a, CD207 (Langerin), S100, and cyclin D1; CD68 shows a paranuclear dot pattern, and BRAF V600E (VE1) staining supports the diagnosis when present.[8] Combined CD1a and CD207 positivity is diagnostically decisive, and cyclin D1 helps separate LCH from reactive Langerhans-cell collections.[8] Birbeck granules on electron microscopy are classic but no longer required given reliable immunohistochemistry.[25] VE1 immunostaining is neither fully sensitive nor specific, so concurrent molecular testing is recommended.[8]

Molecular findings and correlation

Clonal MAPK-pathway activation underlies LCH: BRAF V600E is present in roughly half of cases (reported in series up to ~57%–69%), with BRAF indels, MAP2K1, ARAF, and N/KRAS mutations and rare kinase fusions accounting for most remaining cases.[2][4][8][27] Confirmation of a clonal driver supports the diagnosis over reactive mimics and identifies actionable targets.[8] Radiologic–pathologic correlation is essential because the benign cytology belies a genuinely destructive, mutation-driven lesion.[2]

Workup and referral

Biopsy is required for diagnosis, and comprehensive staging confirms whether disease is truly unifocal: history and examination targeting common sites, laboratory evaluation, skeletal assessment, and whole-body FDG-PET/CT where available, with brain/pituitary MRI when CNS-risk sites or arginine vasopressin deficiency are suspected.[8] Multidisciplinary coordination—oral and maxillofacial surgery, pathology, hematology-oncology, and, as needed, endocrinology and radiation oncology—is standard.[14][25]

Definitive treatment

For confirmed solitary jaw bone LCH not involving critical organs or CNS-risk sites, management is deliberately conservative:

• Curettage, often with intralesional corticosteroid, is frequently both diagnostic and therapeutic; gross total resection is not warranted because most lesions remodel after curettage.[3]
• Observation is appropriate for asymptomatic lesions after biopsy confirmation.[8]
• Bisphosphonate or indomethacin can be used for symptomatic bone disease.[8]
• Low-dose radiotherapy is a local option, used mainly in adults and selected cases, but is tempered in growing children by the risk of facial growth disturbance and asymmetry.[8][19]
• Systemic therapy (vinblastine/prednisone) is reserved for progression, multifocal/multisystem disease, or lesions at CNS-risk craniofacial sites.[3]

Recurrence, surveillance, and outcome

Prognosis for single-system, single-site osseous LCH is excellent, with high overall survival.[2][28] In children with unifocal osseous disease managed with watchful waiting, reported 3-year event-free survival is roughly 88%, with most events (new lesions or primary-lesion progression) occurring within the first year—supporting close surveillance during that interval.[20] Even in broader adult cohorts, overall survival is high while reactivation is the main concern, underscoring the need for structured follow-up rather than aggressive upfront therapy.[28] Clinical and imaging follow-up should monitor for local progression and emergence of additional sites.[8][20]

Prognostic factors

Extent of disease is the dominant prognostic determinant—risk-organ (liver, spleen, hematopoietic) involvement drives mortality, which is not a feature of isolated bone disease.[1] Younger age and BRAF V600E positivity are associated with more extensive disease, reactivation, and neurodegenerative complications.[2][4]

CNS-risk craniofacial sites

Not all head and neck bone lesions behave as low-risk local disease. CNS-risk lesions include those of the orbit, temporal/mastoid, sphenoid, zygomatic and ethmoid bones, maxilla, and paranasal sinuses (and of the anterior or middle cranial fossa with intracranial extension); these CNS-risk sites are associated with increased risk of CNS involvement and arginine vasopressin deficiency, and systemic therapy is recommended even for a single lesion at these sites.[3][8] The mandible is not a CNS-risk site, so site mapping within the craniofacial skeleton directly changes treatment intensity.[8]

Pediatric considerations

Because jaw LCH clusters in children and can disturb the developing dentition and facial skeleton, treatment selection weighs long-term growth effects; radiotherapy is used cautiously given the risk of facial asymmetry, favoring curettage, intralesional steroid, or observation when feasible.[11][19] In children, a jaw lesion also warrants vigilance for leukemia and other malignant mimics during the diagnostic workup.[13][24]